Sellas Life Sciences is trading 6.6% down today at $12.03 as investors rebalance risk and take profits following a period of heavy volatility.
- Shares are experiencing a pullback after a sharp run-up driven by institutional buying and significant call option activity.
- Market participants are closely watching for Phase 3 REGAL trial results for the company's AML therapy, GPS, leading to increased price sensitivity.
- The decline comes amid options-heavy trading as the market adjusts positions ahead of clinical milestones for its leukemia program.